Sons And Daughters Of BBCMF High Technologies Companies, It, R & D, domestic, international

[mick]

maybe this one? lot of vaccine stuff. VXGN

VAXGEN INC (Other OTC:VXGN.PK) Delayed quote data

Last Trade: 9.09
Trade Time: Nov 25
Change: 0.14 (1.56%)
Prev Close: 8.95
Open: 8.90
Bid: N/A
Ask: N/A
1y Target Est: 24.00

Day's Range: 8.87 - 9.20
52wk Range: 7.79 - 20.00
Volume: 49,384
Avg Vol (3m): 305,294
Market Cap: 227.95M
P/E (ttm): N/A
EPS (ttm): -1.52
Div & Yield: N/A (N/A)


1d 5d 3m 6m 1y 2y 5y max

The Five Dumbest Things on Wall Street This Week


Add VXGN.PK to Portfolio Set Alert Download Data

HEADLINES Change Display [ hide $$ edit ]
• Data Regarding Micro Needle Intradermal Delivery of VaxGen's Anthrax Vaccine Presented at American Association of Pharmaceutical Scientists Meeting
PR Newswire (Tue, Nov 8)
• BiodefenseStocks.com Reports on Project BioShield; Working to Defend Against Bioterrorism Through a Stronger Biodefense Arena
Market Wire (Fri, Nov 4)
• VaxGen to Present at CIBC World Markets 16th Annual Healthcare Conference
PR Newswire (Fri, Nov 4)
• VAXGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Wed, Nov 2)
• VaxGen to Hold Conference Call and Webcast on Wednesday, Nov. 2
PR Newswire (Tue, Nov 1)
• UPDATE - VaxGen delays anthrax vaccine delivery to US
at Reuters (Tue, Nov 1)
• VaxGen to file late financial reports in 2006
bizjournals.com (Tue, Nov 1)
• VaxGen Provides Update Regarding Financial Statements and Anthrax Vaccine Program
PR Newswire (Tue, Nov 1)
• VAXGEN INC Files SEC form 8-K, Entry into Material Agreement, Financial Statements and Exhibits
EDGAR Online (Mon, Oct 31)
• VaxGen to Present at BIO Investor Forum 2005
PR Newswire (Tue, Oct 18)
More Headlines for VXGN.PK...
Add VXGN.PK News to My Yahoo!:


REPORTS
BiotechWatch's profile of VaxGen tracks products in clinical development, cash...
Nov 16 - BiotechWatch LLC
ValuEngine Quantitative Industry Report for BIOTECHNOLOGY
Nov 16 - ValuEngine, Inc.
SharkRepellent.net Takeover Defense Profile: VaxGen, Inc.
Nov 15 - TrueCourse, Inc.
More Reports for VXGN.PK...


KEY STATISTICS
Forward P/E (1 yr): N/A
P/S (ttm): 15.70
Dividend Date: N/A
Ex-Dividend Date: N/A

More Key Statistics...

ANALYST
Annual EPS Est (Dec-05) : -2.17
Quarterly EPS Est (Sep-05) : N/A
Mean Recommendation*: 1.3
PEG Ratio (5 yr expected): N/A


* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
VaxGen, Inc. engages in the development, manufacture, and commercialization of biologic products for the prevention and treatment of human infectious disease. more


Company Profile - Industry